On May 4, the European Medicines Agency (EMA) began continuous monitoring of the Chinese COVID-19 vaccine manufactured by Sinovac to assess its effectiveness and safety. This is reported by the Associated Press.
“The decision to initiate an ongoing review is based on the preliminary results of laboratory studies (preclinical data) and clinical studies. These studies find that the vaccine causes the production of antibodies targeting SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease, ” the European Medicines Agency said in a statement.
It is also noted that the EMA will evaluate the data as it becomes available to decide whether the benefits outweigh the risks.
In addition, the agency reports: the current review will continue until there is enough evidence for a formal application for a sales permit.